CASE-04 · Pharma & clinical development
Taking the drug «BX-204» to Phase III: €180 million over three years
79
Pharma
Pharma
The result is a statistical mirage — and the benchmark is about to change.
In one line Avoided a €180M trial potentially aimed at the wrong target.
The Chief Medical Officer of clinical development, with a €180 million program already in start-up and an executive committee demanding to move before the competitor reaches the finish line.
A mid-sized pharmaceutical company with a single molecule in advanced development. BX-204 is a candidate for a niche oncology indication — few patients, high unmet need, high expected price. The Phase III budget is the company's largest bet in the past decade.
The Phase II signal arrived unevenly: two of the twelve enrolment centers contributed more than half of the total response, and the biomarker-positive subgroup showed an effect almost double that of the general population. In oncology literature, this pattern — response driven by a few expert centers or a narrow subgroup — recurs regularly in Phase III failures: the effect does not replicate across the more heterogeneous population of large trials. At the same time, the main competitor has released preliminary data on an agent with a different mechanism of action that could redefine the standard-of-care protocol within eighteen to twenty-four months. If the reference comparator changes, the current trial design loses regulatory validity.
Internal pressure is strong: Phase II data are positive, the competitive window is narrow, and every month of waiting burns resources and gives ground to the competitor. But the red team points to a detail management prefers not to isolate: strip out the two best centers and the biomarker cohort, and the residual effect is modest — probably insufficient for approval. Starting now means committing €180 million to a design that may not replicate, chasing a comparator that could become obsolete before the final readout. Waiting — or redesigning — costs time, but avoids running toward a moving target.
Estimated relative response in the total Phase II population vs the biomarker-positive subgroup — the gap signals a non-replication risk (illustrative data).
Share of total response attributable to each enrolment center — the two expert centers account for over half the overall signal (illustrative data).
The result could be a statistical mirage. Much of the signal comes from a single patient subgroup and from two centers especially good at enrolling: on the true average, the effect is modest. And meanwhile a competitor is about to change the standard of care — the yardstick. You risk a €180 million trial aimed at a target that will soon no longer exist.
Provenance: Phase II data (by center and subgroup) · literature on the indicator · competitor intelligence · red-team base.
Composite cases, in the method of the Harvard Business Review: reconstructions based on real, recurring situations in each sector, merged and anonymized to protect confidentiality. The decision dynamics are authentic; names, figures and details are altered and not traceable to any single client or case. The «provenance» notes describe the type of evidence the engine cites with traceability in production. The Δ-CSI values illustrate the intensity of the pressure the contradiction put on the assumptions.